Efficacy, safety, tolerability, and satisfaction of N-acetylcysteine and pentoxifylline in lichen planopilaris patients under treatment with topical clobetasol : A triple arm blinded randomized controlled trial
© 2022 Wiley Periodicals LLC..
Lichen planoplaris (LPP) is one of the most common causes of inflammatory cicatricial alopecias. There is no definitive cure for the disease and most of the available therapeutic options can potentially lead to serious complications following their use for extended durations. In this study, we aimed to evaluate the efficacy, safety and tolerability of N-acetylcysteine (NAC) and pentoxyfillin (PTX), as adjunctive therapies, in the management of LPP. In a randomized, assessor- and analyst-blinded controlled trial, patients with proven LPP were randomly assigned to three groups of 10. Group I (the control group) received clobetasol 0.05%lotion; Group II, a combination of clobetasol 0.05% lotion and oral PTX; Group III, a combination of clobetasol lotion 0.05% and oral NAC. Lichen planopilaris activity index (LPPAI), the possible side effects, tolerability and patients satisfaction were assessed before and two and four months after the initiation of the treatments. Thirty patients, 96.7% women, with a mean age of 46.8 ± 13.3 years old, were included in the study. Four months into the treatments, the overall LPPAI and the severity and/or frequency of most of its determinants significantly decreased in all groups. In a comparison among the groups, patients who received either of the combination therapies showed more decline in their LPPAI than those receiving only clobetasol. The decline was more noticeable and statistically significant only in the NAC group. Three patients in the PTX group developed complications that were not statistically significant when compared with the other groups. There were no substantial differences in the tolerability of the treatments among the study arms. The use of oral NAC and PTX added to the therapeutic efficacy of topical clobetasol in the treatment of LPP, suggesting that they might be beneficial and safe adjuvant therapies and add to the efficacy of topical treatment without any noticeable impact on the adverse effects experienced by patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Dermatologic therapy - 35(2022), 8 vom: 22. Aug., Seite e15639 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ahmadi Kahjoogh, Hossein [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.08.2022 Date Revised 05.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dth.15639 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342248332 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342248332 | ||
| 003 | DE-627 | ||
| 005 | 20231226013651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dth.15639 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1140.xml |
| 035 | |a (DE-627)NLM342248332 | ||
| 035 | |a (NLM)35703373 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ahmadi Kahjoogh, Hossein |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy, safety, tolerability, and satisfaction of N-acetylcysteine and pentoxifylline in lichen planopilaris patients under treatment with topical clobetasol |b A triple arm blinded randomized controlled trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.08.2022 | ||
| 500 | |a Date Revised 05.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a Lichen planoplaris (LPP) is one of the most common causes of inflammatory cicatricial alopecias. There is no definitive cure for the disease and most of the available therapeutic options can potentially lead to serious complications following their use for extended durations. In this study, we aimed to evaluate the efficacy, safety and tolerability of N-acetylcysteine (NAC) and pentoxyfillin (PTX), as adjunctive therapies, in the management of LPP. In a randomized, assessor- and analyst-blinded controlled trial, patients with proven LPP were randomly assigned to three groups of 10. Group I (the control group) received clobetasol 0.05%lotion; Group II, a combination of clobetasol 0.05% lotion and oral PTX; Group III, a combination of clobetasol lotion 0.05% and oral NAC. Lichen planopilaris activity index (LPPAI), the possible side effects, tolerability and patients satisfaction were assessed before and two and four months after the initiation of the treatments. Thirty patients, 96.7% women, with a mean age of 46.8 ± 13.3 years old, were included in the study. Four months into the treatments, the overall LPPAI and the severity and/or frequency of most of its determinants significantly decreased in all groups. In a comparison among the groups, patients who received either of the combination therapies showed more decline in their LPPAI than those receiving only clobetasol. The decline was more noticeable and statistically significant only in the NAC group. Three patients in the PTX group developed complications that were not statistically significant when compared with the other groups. There were no substantial differences in the tolerability of the treatments among the study arms. The use of oral NAC and PTX added to the therapeutic efficacy of topical clobetasol in the treatment of LPP, suggesting that they might be beneficial and safe adjuvant therapies and add to the efficacy of topical treatment without any noticeable impact on the adverse effects experienced by patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a N-acetylcysteine | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a lichen planopilaris | |
| 650 | 4 | |a pentoxifylline | |
| 650 | 4 | |a randomized clinical trial | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a satisfaction | |
| 650 | 4 | |a topical clobetasol | |
| 650 | 7 | |a Clobetasol |2 NLM | |
| 650 | 7 | |a ADN79D536H |2 NLM | |
| 650 | 7 | |a Pentoxifylline |2 NLM | |
| 650 | 7 | |a SD6QCT3TSU |2 NLM | |
| 650 | 7 | |a Acetylcysteine |2 NLM | |
| 650 | 7 | |a WYQ7N0BPYC |2 NLM | |
| 700 | 1 | |a Yazdanian, Nafise |e verfasserin |4 aut | |
| 700 | 1 | |a Behrangi, Elham |e verfasserin |4 aut | |
| 700 | 1 | |a Roohaninasab, Masoumeh |e verfasserin |4 aut | |
| 700 | 1 | |a Hejazi, Pardis |e verfasserin |4 aut | |
| 700 | 1 | |a Goodarzi, Azadeh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatologic therapy |d 1998 |g 35(2022), 8 vom: 22. Aug., Seite e15639 |w (DE-627)NLM096394870 |x 1529-8019 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2022 |g number:8 |g day:22 |g month:08 |g pages:e15639 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dth.15639 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2022 |e 8 |b 22 |c 08 |h e15639 | ||